Filters
Documents containing immun
Showing 25 of 136 items meeting your criteria.
| Type | Category | Supplier | ||
|---|---|---|---|---|
 | Cancer remains one of the most active areas of biomedical research, driving continuous advances in immunotherapy, targeted therapeutics, biomarker discovery, and precision medicine. To support cancer research from basic biology to translational studies, Abnova offers a comprehensive portfolio of antibodies, recombinant proteins, and ELISA kits covering key oncology pathways and targets.
This catalog highlights antibodies, recombinant proteins, and ELISA kits supporting research in Immuno-Oncology, Cell Therapy, Targeted Therapy, Biomarkers, DNA Repair, Tumor Microenvironment, Cell Signaling, Cancer Stem Cells, Tumor Suppressors, Cell Death, Hematologic Oncology, and Cancer Metabolism. Our products are designed to support studies in tumor biology, immune regulation, therapeutic target validation, biomarker development, and drug discovery. | |||
Documents | Cancer | Abnova Corporation | ||
 | Biologics development requires accurate quantification and reliable immunogenicity assessment to ensure safety and efficacy. Abnova provides Biosimilar and Immunogenicity Research Tools to support key workflows from drug measurement to immune response evaluation.
Abnovas portfolio includes biosimilar antibodies and ELISA kits for comparative and PK studies, as well as ADA reagents and ELISA kits for immunogenicity assessment. These solutions provide high sensitivity and reproducibility, enabling efficient and consistent research outcomes. | |||
Documents | Immunology | Abnova Corporation | ||
 | ELK Biotechnology is a high-tech biological company focusing on the development and production of immunological products and molecular biology products. | |||
Documents | Catalogue | ELK Biotechnology | ||
 | Cytokines are small proteins or peptides secreted by immune and non-immune cells. They act as signaling molecules between cells and play a central role in immune regulation, inflammatory responses, hematopoiesis, tissue repair, and development. Research on cytokines provides a scientific foundation for the prevention, diagnosis, and treatment of
diseases in clinical practice. | |||
Documents | Cytokines | ELK Biotechnology | ||
 | Founded in 2013 in Wuhan Precision Medical Industry Base, ELK Biotechnology is a high-tech biological enterprise specializing in life science and immunity research. The company has 6000㎡ Iaboratory, with independent cell culture room and SPF animal room, specializing in the introduction and development of morphological pathology, cell biology, molecular biology, protein immunology, model animal related products. Its products include 8500+ ELISA kits,70+ molecular biology products and 15,000+ proteins and antibodies for scientific research. Through unremitting efforts, our products have been sold to more than 80 countries. | |||
Documents | Molecular Biology | ELK Biotechnology | ||
 | ImmunoMetrix™ is a premier line of monoclonal antibodies originated and rigorously characterised by the Clinical Proteomic Tumour Analysis Consortium (CPTAC) standards. By combining the CPTACs unrivalled validation standards with Leincos 30+ years of manufacturing excellence, we provide the most reliable affinity reagents available for cancer research. | |||
Documents | Antibodies | Leinco Technologies | ||
 | As organoid models grow in complexity, the demand for antibodies that can perform in dense 3D environments is critical. Leincos catalog is engineered to provide high penetration, low background, and physiological safety for tumor-immune co-cultures and spatial phenotyping. | |||
Documents | Antibodies | Leinco Technologies | ||
 | TargetMol offers hundreds of products for disease modelling, covering a wide range of disease models including cancer, neurological disorders, immune and inflammatory conditions, endocrine and metabolic diseases, as well as cardiovascular diseases. | |||
Documents | Catalogue | TargetMol | ||
 | T Cell Immunoreceptor with Immunoglobulin and ITIM domains (TIGIT, VSTM3) is an immune checkpoint receptor expressed on the surface of cytotoxic, memory and regulatory T cells
(Tregs) as well as natural killer (NK) cells. TIGIT binding to CD155 (PVR) and CD112 (Nectin-2) suppresses immune activation on cytotoxic T cells and NK cells. In the normal immune system, the suppressive effect of TIGIT is counterbalanced by the immune-activating receptor CD226 (DNAM1), which competes with TIGIT to bind CD155 and CD112. The inhibitory signal provided by TIGIT overpowers the ability of CD226 to stimulate T cell activation. Tumor cells exploit the dominance of the inhibitory TIGIT pathway to avoid immune-mediated destruction. Overexpression of TIGIT and reduced CD226 activity are frequently observed in exhausted T cells within tumors, making the TIGIT/CD226 axis a key focus for immune checkpoint blockade strategies. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
 | PD-1 (Programmed Cell Death Protein 1; CD279) is a type I transmembrane protein belonging to the CD28/CTLA-4 family of immune receptors. PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC;
CD273) are immuno-coinhibitory ligands of the B7 family binding to PD-1. The PD-1/PD-L1 or PD-L2 signaling pathway is a negative regulatory mechanism that inhibits T cell proliferation and cytokine production. Blockade of the PD-1/PD-L1 interaction enhances antitumor immunity. The PD-1 pathway plays a major role in the inhibition of self-reactive T cells and protection against autoimmune diseases. PD-1 and PD-L1 also exist as soluble forms. Elevated levels of soluble PD-1 (sPD-1) are shown in rheumatoid arthritis, skin sclerosis and autoimmune hepatitis. Levels of sPD-L1 are increased in the plasma of cancer patients as well as in cerebrospinal fluid of gliomas. sPD-L1 is a biomarker of poor survival in patients with B cell lymphoma, renal cell carcinoma, metastatic melanoma or lung cancer and is associated with advanced tumor stages. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
 | Beyond the well-characterized B7-1 (CD80), B7-2 (CD86) and PD-L1/PD-L2 pathways, newer B7 family ligands, B7-H3, B7- H4, B7-H5 (VISTA) and B7-H6, have emerged as important regulators of immune responses with significant interest in immunotherapy research. They are all overexpressed in tumors correlating with immune escape and resistance to antitumor
responses. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
 | The herpesvirus entry mediator (HVEM; CD270; TNFRSF14) represents a central hub in immune regulation, orchestrating complex interactions with multiple partners, including BTLA, LIGHT
and CD160. HVEM is a molecular switch that acts both as an immune system stimulator and as an inhibitor. It is expressed in T cells, B cells, natural killer cells, dendritic cells and endothelial cells. LIGHT is an immune stimulator that contributes to dendritic cell maturation and T cell expansion. The immune suppressor BTLA functions in opposition to LIGHT by inhibiting naïve T cell expansion and induction of Treg cells. CD160 acts as an immune suppressor through its interactions with HVEM. The checkpoint receptors/ligands system HVEM, LIGHT, CD160 and BTLA (CD272) is part of a complex network of overlapping receptor interactions that function in both immune stimulation and suppression and which is a potential therapeutic target for treatment of autoimmune diseases and allergies and controlling antitumor responses. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
| OX40 (CD134; TNFRSF4) is an activating receptor, a member of the TNF receptor superfamily, expressed on the surface of activated cytotoxic T cells and regulatory T cells (Tregs). OX40 both activates and amplifies T cell responses. On cytotoxic T cells, OX40 binds to its ligand OX40L (CD252; TNFSF4), resulting in stimulatory signals that promote T cell reproduction, function and survival. OX40/OX40L signaling blocks the ability of Tregs to suppress T cells and reduces Treg generation. By inhibiting the immunosuppressive effect of Tregs and limiting their population, OX40 further amplifies the impact of T cell activation. The dual effects of OX40 help to create a tumor microenvironment that is more favorable to the antitumor immune response. The OX40-OX40L axis is a versatile and promising target across oncology, autoimmunity, and chronic inflammatory disease research. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
 | Inducible T Cell Co-Stimulator (ICOS; CD278) is an activating receptor expressed on the surface of activated cytotoxic T cells, regulatory T cells (Tregs), natural killer (NK) cells and other types of T cells, having a distinct and opposing function than CTLA-4. The ligand ICOSL (B7-H2; CD275) is expressed on antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages. ICOS/ICOSL signaling leads to the activation, proliferation and survival of cytotoxic T cells, as well as the survival of memory T cells. ICOS/ICOSL binding generates various activities including T cell activation and effector functions and when sustained also suppressive activities mediated by regulatory T cells. This dual role in both anti-tumor and pro-tumor activities makes targeting the ICOS/ICOSL pathway attractive for enhancement of anti-tumor immune responses and as a potential biomarker for disease treatment and prognostic prediction. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
 | Lymphocyte-activation Gene 3 (LAG-3; CD223) is an immune checkpoint receptor expressed on the surface of both activated cytotoxic T cells and regulatory T cells (Tregs). LAG-3 expression limits both the expansion of activated T cells and the size of the T cell memory pool. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
 | Glucocorticoid-induced TNFR-related protein (GITR; CD357; TNFRSF18) is an activating receptor on the surface of T cells and other immune cells, binding to its ligand GITRL (TNFSF18). Once exposure to tumor antigen activates a T cell, the number of GITR receptors on its surface increases. On the activated T cell, GITR acts as a co-stimulatory receptor, meaning that it is a receptor whose signaling enhances cell reproduction and the generation of cancer-killing activity. Activation of GITR signaling can also help to enhance immunity through the activation of cytotoxic T cells and inhibition of Treg activity. The GITR/GITRL pathway can shift the immune balance toward anti-tumor immunity by strengthening effector T cell responses and weakening tumor-protective regulatory networks but also play a dual role in autoimmunity. While its activation can help control tumor growth, excessive stimulation may promote autoreactive T cell activity, aggravating autoimmune inflammation. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
 | Cytotoxic T Lymphocyte Antigen 4 (CTLA-4; CD152) is an immune checkpoint receptor expressed on the surface of activated T cells. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
 | TIM-3 plays an important role in autoimmune diseases, chronic viral infections and tumors. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
 | CD137 (4-1BB; TNFRSF9) is an activating receptor binding to CD137L (4-1BBL; TNFSF9). Because CD137 is expressed on both natural killer (NK) cells and T cells, it can trigger both innate and adaptive immunity. After these cells have been activated by exposure to tumor antigen, CD137 signals stimulate them to reproduce and to generate antitumor activity. CD137 has been shown to play a critical role on T cells in the development of immune memory and the creation of a durable immune response. On lymphocytes, the presence of CD137 appears to be a marker for tumor reactivity. Activation of CD137 signaling can stimulate both cytotoxic T cell and NK cell activity and generate a lasting memory response. Bidirectional CD137/ CD137L signaling also plays an important role in the pathogenesis of autoimmune diseases. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
 | The CD40-CD40L (CD154) signaling pathway is a pivotal regulator of adaptive immunity, bridging innate and adaptive responses. CD40, a member of the TNF receptor superfamily, is
expressed on antigen-presenting cells (APCs) such as dendritic cells, macrophages and B cells, while its ligand CD40L is transiently expressed on activated CD4+ T cells. Engagement of CD40 by CD40L drives a cascade of immune-activating events. In dendritic cells and macrophages, CD40 signaling enhances antigen presentation, cytokine secretion and upregulation of costimulatory molecules. In B cells, CD40-CD40L interactions promote germinal center formation, isotype switching and the generation of long-lived plasma cells and memory B cells. Interaction between CD40-CD40L stimulates cytokines secretion of B cells with subsequent T cell activation and antitumor immunity. | |||
Documents | Immunology | AdipoGen Life Sciences | ||
 | ProSci supplies high-yield polyclonal antibodies derived from chickens raised and immunized in the Unites States, delivering consistent, milligram-scale quantities of IgY. | |||
Documents | Service | ProSci | ||
 | Leukopaks provide enriched peripheral blood mononuclear cells (PBMCs)with low granulocytes and red blood cells. They are a vital source material forimmunological studies, cell therapy research, and pharmaceuticaldevelopment. The collection and processing of the material requires tightcoordination between the sourcing and laboratory teams to collect, processand cryopreserve large number of samples within the ideal time of less than 24hours. Here, we demonstrate that by cryopreserving Leukapheresis materialand primary cells logistical issues are eliminated, providing convenience inthe timing of experiments, lowering costs of research and development of newtherapies, and allowing future access to same lot samples for additionalstudies. However, the impact of cryopreservation of Leukopaks and primarycells efficacy have been mixed. To demonstrate the shelf life of cryopreservedLeukopaks we performed a year long stability study demonstrating that theviability of the products remains above 95% post-thaw. We also performedbulk isolations of primary cells such as MNCs, CD3+ T Cells and CD56+ NKcells from 10 Billion TNC Leukopaks, from 20 donors to demonstrate anaverage cost saving initiative for the biotech industry of about $57K per donorfor the MNC isolation, $91K per donor for the CD3+T Cell isolation, and$12K per donor for the CD56+ NK Cell isolation. | |||
Documents | Biological Samples | CGT Global | ||
 | Elabscience® has established advanced antibody development platforms that generate over 17,000 high-quality antibodies. Our antibody products support research in life science and medicine, including cell biology, cancer, neurobiology, epigenetics, infectious diseases, and immunology. | |||
Documents | Antibodies | Elabscience | ||
 | Abnova provides a broad and versatile ELISA portfolio spanning more than 20 research areas, including oncology, immunology, metabolism, neuroscience, infectious disease, toxicology, bioprocess monitoring, and veterinary science. | |||
Documents | ELISA | Abnova Corporation | ||
 | Whartons Jelly is a rich source of highly proliferative, multipotent, Mesenchymal Stem Cells. These cells are known to be highly immunomodulatory and capable of trilineage differentiation.
CELLvo™ human Mesenchymal Stem Cells - Whartons Jelly (MSC-WJ) have been isolated and cultured under xeno-free conditions on the CELLvo™ XF Matrix. CELLvo™ MSC-WJ proliferate more quickly, have a smaller cell size, and show a higher percentage of SSEA4 (+) cells as compared to Whartons Jelly MSCs isolated and cultured on other substrates. | |||
Documents | Cell Culture | StemBioSys | ||